From the American Academy of Ophthalmology

This analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study confirms the initial report: intensive treatment of glycemia slows progression of retinopathy in patients whose average age and diabetes duration were 62 and 10 years, respectively, and who had cardiovascular disease or cardiovascular risk factors. Patients with mild retinopathy appeared to benefit most. Additionally, progression slowed in patients treated with fenofibrate. This is the second study to confirm the benefits of fenofibrate. Ophthalmology, December 2014